GlassScriptPhysician profile
Sandra Bushman
NPI 1215262969
$1,579.27
in general payments reported to CMS, 2019-2025
24 companies · $766 in 2025
The $766 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.98 · 2022: $49.77 · 2023: $110 · 2024: $630 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.41 | 2022-2025 | |
| Corium, LLC | $267.91 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $228.40 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.17 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $65.62 | 2024-2025 | Ozempic, Rybelsus |
| Tris Pharma INC | $56.04 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $47.01 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $37.89 | 2025 | Nexplanon |
| Pfizer INC. | $37.83 | 2024-2025 | |
| Amgen INC. | $35.87 | 2024-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $32.15 | 2024-2025 | Airsupra, Breztri |
| Lundbeck LLC | $29.37 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $28.29 | 2025 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $26.76 | 2024 | Rexulti |
| Harmony Biosciences LLC | $24.48 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $23.98 | 2021 | |
| Collegium Pharmaceutical, INC. | $19.26 | 2025 | Jornay Pm |
| Lilly USA, LLC | $18.22 | 2022 | |
| Glaxosmithkline, LLC. | $17.07 | 2023 | Trelegy Ellipta |
| Indivior INC. | $16.68 | 2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $16.49 | 2023 | Jornay Pm |
| Philips North America LLC | $15.85 | 2024 | (Ck7) Extended Holter |
| Seqirus USA INC | $15.35 | 2025 | Flucelvax, Fluad |
| Astellas Pharma US INC | $14.17 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Bushman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.